Brent is General Partner (West Coast) at Canaan Partners. Brent joined Canaan in 1999 and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent's current investment and Board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs and pain management developer Semnur. Some of his previous companies include Dexcom (DXCM), Revivant (acquired by Zolle), Peninsula Pharmaceuticals (acquired by J&J), Cerexa (acquired by FRX and Spinifex Pharmaceuticals (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J) and IAP Research. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in mechanical engineering from the University of Dayton.
Patrick Heron is a Managing General Partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003.
Throughout his 13 years as a General Partner, Patrick has led or co-led investments across nearly 20 companies. He has been active in company formation around both early- and later-stage assets. He has led and served as a director for many successful Frazier Life Sciences investments, including ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda), and Collegium (NASDAQ: COLL).
In addition to ScoutBio’s Board of Directors, Patrick currently serves on the boards of Flashlight Therapeutics, Imago BioSciences, Iterum Therapeutics, Mirum Pharmaceuticals, Silvergate Pharmaceuticals, and SutroVax.
Patrick received his MBA from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he was a Phi Beta Kappa graduate and Morehead Scholar.
Shelley joined Abingworth in 2015 and invests across a broad range of therapeutic areas and stages of development, from start-ups to late-stage. She has over 15 years of operating and investment experience in the biopharmaceutical industry, including most recently Gilead where she led R&D Strategy and Business Development in Oncology, Immunotherapy and Hepatitis B. Previously Shelley invested and co-founded biotechnology companies at Frazier Healthcare Ventures. Earlier in her career she was an investment professional at Flagship Ventures and a management consultant to healthcare and biotech companies at McKinsey.
Shelley holds an MD and PhD in Biochemistry and Biophysics from UCSF, and received her BA in Molecular Biology from Princeton University. She is a first author of publications in Science and other prominent journals and a Co-Chair of the Princeton Alumni School Committee.